Recent Updates
Recently added Catalysts

CP-547, 632

Phase 2

Ovarian Neoplasms | Small molecule | Oncology |Pfizer, Inc.|Last Updated: Nov 9, 2006

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment29

FDA Designations

No designations recorded

Clinical trial landscape

CP-547, 632 · 2 trials · 4 indications

Phase 2 1Phase 1 1
NCT00074867Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube CancerOvarian Neoplasms
COMPLETED29 Analytics
PHASE2COMPLETED
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
Ovarian Neoplasms
NCT0007486729
Unlock trial analytics

Study Endpoints

Primary Endpoints

At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial.
Statistical estimates used on the Stage 1 data indicated low likely-hood of a positive outcome if the study continued to Stage 2. This provided the basis for discontinuation of the trial.

Secondary Endpoints

Given the outcome of the primary objective, analysis of secondary objectives were not formalized.
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
CP-547,632DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Histologically proven epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancerRecurrent or persistent elevated CA-125. * For the purpose of this study, elevated CA-125 is defined as a value of ≥40 U/ml on two separate consecutive determinations m...

Countries:United StatesCanada
Unlock Eligibility Criteria

Frequently asked questions about CP-547, 632

What is CP-547,632 used for?

CP-547,632 is an investigational small molecule being studied for the treatment of ovarian neoplasms and lung neoplasms. It was evaluated in clinical trials for these oncology indications, including a Phase 1 study in lung cancer and a Phase 2 study in ovarian, peritoneal, and fallopian tube cancer.

What does CP-547,632 target?

CP-547,632 is an oral tyrosine kinase inhibitor that targets VEGFR-2, based on the clinical trial titles describing it as a tyrosine kinase inhibitor of VEGFR-2. It was studied in combination with chemotherapy for lung neoplasms and as a single agent for small-volume ovarian, peritoneal, and fallopian tube cancer.

Who makes CP-547,632?

CP-547,632 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company sponsored the clinical trials evaluating this investigational oncology drug.

What phase is CP-547,632 in?

CP-547,632 is an investigational drug that has completed clinical development. It was studied in a Phase 1 trial for lung neoplasms and a Phase 2 trial for ovarian, peritoneal, and fallopian tube cancer, both of which are completed. It is not FDA approved.

What clinical trials is CP-547,632 in?

CP-547,632 has been studied in two completed clinical trials. NCT00074854 was a Phase 1 study in lung neoplasms with 87 participants, and NCT00074867 was a Phase 2 study in ovarian, peritoneal, and fallopian tube cancer with 29 female participants. Both trials were conducted in the United States and Canada.

Is CP-547,632 the same as any other drug?

CP-547,632 is the primary name for this investigational compound, and no alternative names have been reported in the clinical trial records. It is a distinct small molecule tyrosine kinase inhibitor being developed by Pfizer for oncology indications.